Expert Insight: Advancing oncology therapeutics development with 2D & 3D cell screening Catch up on this expert webinar to discover the customizable screening service helping to drive the validation of novel cancer therapies 06 May 2021 Vicki Racicot, Field Application Scientist, Horizon Discovery The utilization of robust, high-throughput methods for screening in 3D models, including cell line-derived spheroids and patient-derived organoids, has the potential to revolutionize cancer therapy development, enhancing both the determination of mode of action and expanding indications, as well as improving the clinical relevance of therapeutic efficacy studies. In this SelectScience webinar, now available on demand, Field Application Scientist Vicki Racicot highlights recent data generated by Horizon Discovery from 2D cell panel single-agent and combination screens and illustrates how these can complement CRISPR screening results to drive the validation of potential oncology-relevant therapeutic targets. Racicot also reveals how data generated from 3D cell panel screening approaches can enrich the understanding of oncology therapeutics efficacy in the context of more complex